Oncology News | pharmaphorum

News

Boehringer Ingelheim, Biberach, Germany, February 2007

BI investigates cancer 'dark antigens' with UK's Enara

Boehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight cancer using “dark antigens” in a deal worth up to €876 million ($1.07b

News

bluebird bio to split into oncology and gene therapy special...

US biotech bluebird bio has announced plans to split into two this year, with a separate oncology business spinning off as the company prepares to bring its products to market.

News

Oxford BioTherapeutics to research cell therapies for Gilead...

Gilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch of cell therapy products for solid tumours and blood cancers.

News

Roche nabs breakthrough tag for TIGIT cancer immunotherapy

Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA.

News

BMS calls time on brain cancer trial as Opdivo misses second...

Bristol Myers-Squibb has put out another downbeat “update” announcement about its immunotherapy Opdivo in an aggressive form of brain cancer, saying that it looks unlikely to produce a surv

News

Roche claims EU okay for Herceptin/Perjeta combination Phesg...

Roche has secured EU approval for Phesgo, a fixed-dose combination of its breast cancer drugs Herceptin and Perjeta that is easier and cheaper to administer to patients – and also provides

BI investigates cancer 'dark antigens' with UK's Enara

bluebird bio to split into oncology and gene therapy special...

Oxford BioTherapeutics to research cell therapies for Gilead...

Roche nabs breakthrough tag for TIGIT cancer immunotherapy

BMS calls time on brain cancer trial as Opdivo misses second...

Roche claims EU okay for Herceptin/Perjeta combination Phesg...

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks